256 related articles for article (PubMed ID: 29751367)
1. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.
Li H; Hu J; Luo X; Bode AM; Dong Z; Cao Y
Cancer Sci; 2018 Jul; 109(7):2101-2108. PubMed ID: 29751367
[TBL] [Abstract][Full Text] [Related]
2. Latent and lytic Epstein-Barr virus replication strategies.
Tsurumi T; Fujita M; Kudoh A
Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
[TBL] [Abstract][Full Text] [Related]
3. Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation.
Tan H; Gong Y; Liu Y; Long J; Luo Q; Faleti OD; Lyu X
Biomed Pharmacother; 2023 Aug; 164():114916. PubMed ID: 37229802
[TBL] [Abstract][Full Text] [Related]
4. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis.
Li H; Liu S; Hu J; Luo X; Li N; M Bode A; Cao Y
Int J Biol Sci; 2016; 12(11):1309-1318. PubMed ID: 27877083
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L; Yang M; Yuan Y; Li X; Kuang E
Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
9. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.
Borozan I; Zapatka M; Frappier L; Ferretti V
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093097
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
14. The lytic phase of Epstein-Barr virus plays an important role in tumorigenesis.
Liang Y; Zhang Y; Luo B
Virus Genes; 2023 Feb; 59(1):1-12. PubMed ID: 36242711
[TBL] [Abstract][Full Text] [Related]
15. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
Neparidze N; Lacy J
Clin Adv Hematol Oncol; 2014 Jun; 12(6):358-71. PubMed ID: 25003566
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer.
Zhao J; Jin H; Cheung KF; Tong JH; Zhang S; Go MY; Tian L; Kang W; Leung PP; Zeng Z; Li X; To KF; Sung JJ; Yu J
Cancer; 2012 Feb; 118(4):924-36. PubMed ID: 21717425
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus).
Song H; Lim Y; Im H; Bae JM; Kang GH; Ahn J; Baek D; Kim TY; Yoon SS; Koh Y
Sci Rep; 2019 Mar; 9(1):3465. PubMed ID: 30837539
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies.
Xu M; Zhang WL; Zhu Q; Zhang S; Yao YY; Xiang T; Feng QS; Zhang Z; Peng RJ; Jia WH; He GP; Feng L; Zeng ZL; Luo B; Xu RH; Zeng MS; Zhao WL; Chen SJ; Zeng YX; Jiao Y
Theranostics; 2019; 9(4):1115-1124. PubMed ID: 30867819
[No Abstract] [Full Text] [Related]
20. Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication.
Li Y; Long X; Huang L; Yang M; Yuan Y; Wang Y; Delecluse HJ; Kuang E
J Virol; 2016 Jan; 90(2):887-903. PubMed ID: 26537683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
